Navigation Links
Questcor Pharmaceuticals Reports Strong Finish to 2011
Date:1/6/2012

ANAHEIM, Calif., Jan. 6, 2012 /PRNewswire/ -- In preparation for meetings starting Monday, January 9  with investors and an investor presentation scheduled for 10:00 a.m. Thursday, January 12 at the J. P. Morgan Healthcare Conference, Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the following preliminary operating metrics for the fourth quarter 2011:

      -Approximately 935-950 paid H.P. Acthar® Gel (Acthar) prescriptions for the treatment of multiple sclerosis exacerbations (MS) during the quarter, up approximately 165% from the year ago quarter ended December 31, 2010

      -Approximately 140-150 paid Acthar prescriptions for the treatment of nephrotic syndrome during the quarter, up approximately 145% sequentially from the third quarter of 2011

      -Approximately 120-125 paid Acthar prescriptions for the treatment of infantile spasms (IS) during the quarter, representing a new high for any quarter since Questcor formed its reimbursement support center and began tracking Acthar prescriptions in August 2007

      -3,360 shipped vials of Acthar, up 100% from the quarter ended December 31, 2010.  

 

"Paid prescriptions for all three of our principal therapeutic areas--multiple sclerosis, nephrotic syndrome and infantile spasms--reached new levels in the fourth quarter. These record levels of prescriptions, in combination with vial demand from prior quarter nephrotic syndrome prescriptions, led to record vial shipments and should lead to solid financial results for the quarter," said Don M. Bailey, President and CEO of Questcor Pharmaceuticals. 

"During the past year, our increased investment in the expansion of our selling effort resulted in both increased awareness of the th
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
2. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
3. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
4. Questcor Reports Third Quarter Financial Results
5. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
6. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
7. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
8. Questcor Provides Updated New Paid Prescription Trends
9. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
(Date:9/2/2014)... BARCELONA, Spain , September 2, 2014 ... treatment decisions, including patients, quality of life and treatment ... [ 2 ]   ... ESC Congress 2014, 02 September 2014, ... year results of the PREvention oF thromboembolic events-European Registry ...
Breaking Medicine Technology:Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... , , , , , LOVELAND, Colo. , Feb. 8 Heska Corporation (Nasdaq: ... , , What: Heska Corporation Invites ... Year-End 2009 Earnings Conference Call on the Web, , ... , Where: www.heska.com (click on the Q4 and Year-End 2009 Earnings ...
... DIEGO , Feb. 8 PatientSafe Solutions, Inc., ... that help to eliminate hospital-based medical errors, announced today that ... financing. The financing was led by TPG Biotech, the leading ... TPG Capital. Co-leads for this financing include Camden Partners and ...
Cached Medicine Technology:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast 2PatientSafe Solutions, Inc. Closes $30 Million Financing 2PatientSafe Solutions, Inc. Closes $30 Million Financing 3
(Date:9/2/2014)... News) -- A leading group of oncologists has released ... of advanced breast cancer. HER2-negative breast tumors ... the HER2 protein, the American Society of Clinical Oncology ... Almost 80 percent of women with advanced breast cancer ... this guideline, our aim is to improve both the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... less intensive (and expensive) practice patterns appear to consistently ... unnecessary and excessive medical care, according to a new ... concern about the costs and harms of medical care ... the provision of unnecessary care," said lead author Brenda ... Institute for Health Policy & Clinical Practice. , ...
(Date:9/2/2014)... 02, 2014 Anti-aging is proving ... services such as anti-wrinkle treatments and products, hair ... and breast augmentation becoming much sought after worldwide. ... market intelligence firm Transparency Market Research, the global ... grow to USD 191.7 billion by 2019, from ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur anywhere and ... of destruction. In fact, the United States leads the world ... year. Rainbow International offers the following safety tips on how ... , Select a safe place such as a basement, ... windows to stay during the storm. If a tornado is ...
Breaking Medicine News(10 mins):Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2
... by scientists at Schepens Eye Research Institute may help ... growth factor responsible for creation of new blood vessels, ... scientists mimicked the drugs activity in mice and found ... from leaking from the ventricle into the brain. The ...
... 13 Healthy Coffee,International, Inc. (Pink Sheets: HCFE) ... arm to handle the distribution of Healthy Coffee,drinks ... America and,the world., About Healthy Coffee USA, ... business opportunity component to,Healthy Coffee by providing an ...
... Medical,Affiliates, Inc. (OTC Bulletin Board: UCIA) announced today that ... percent to,$18,259,000 from $17,043,000 for the quarter ended December ... of $381,000 or $.04 per share,for the quarter ended ... share for the quarter ended December 31, 2006. The ...
... Conn., Feb. 13 ,Allscripts, the leading ... solutions that physicians use to improve ... largest primary care medical group in,Connecticut, ... Record (EHR) and,Practice Management (PM) solution ...
... RICHMOND, Va., Feb. 13 A benefit to help ... (VCU) student,Kellie Brown will be held Friday, February 15, ... W. Marshall Street, in Richmond., Kellie Brown was ... appendicitis and an emergency appendectomy had to be,performed. Following ...
... PACS division sign commercial agreement, NEW YORK, ... that it has signed a preliminary agreement with ... ("Toshiba") for,the resale of its MedicRead Colon and ... Corp. is a global leading provider of,diagnostic medical ...
Cached Medicine News:Health News:Healthy Coffee International, Inc. Establishes Healthy Coffee USA, Inc. as Its Marketing Arm 2Health News:UCI Medical Affiliates, Inc. Reports First Quarter Fiscal Year 2008 Results 2Health News:UCI Medical Affiliates, Inc. Reports First Quarter Fiscal Year 2008 Results 3Health News:ProHealth Physicians Selects Allscripts Electronic Health Record and Practice Management for 240 Providers 2Health News:ProHealth Physicians Selects Allscripts Electronic Health Record and Practice Management for 240 Providers 3Health News:Local VA Performers Hold February 15 Benefit to Reduce $10,000 in Medical Bills for Former VCU Student Kellie Brown 2Health News:MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsight's Commercial Agreement with Toshiba PACS Division 2Health News:MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsight's Commercial Agreement with Toshiba PACS Division 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: